Federal Trade Commission Chairwoman Edith Ramirez has issued the following statement regarding today’s release of the EU-U.S. Privacy Shield Framework in Brussels, Belgium. “The EU-U.S. Privacy Shield Framework supports the growing digital economy on both sides of the Atlantic, while ensuring the protection of consumers’ personal information. In providing an important legal mechanism for transatlantic […]
Monthly Archives: February 2016
FTC Puts Conditions on Drug Manufacturer Hikma Pharmaceuticals PLC’s Proposed Acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane, Inc. from Boehringer Ingelheim Corporation
Drug manufacturer Hikma Pharmaceuticals PLC will sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive. The proposed consent order preserves competition by requiring the companies to […]
District Court Ruling Allows FTC to Attempt to Collect Up To $3.2 Million From Marketers Who Deceptively Advertised Homeopathic HCG Diet Direct Drops
As a result of a federal court ruling, the Federal Trade Commission may attempt to collect up to $3.2 million from marketers who lied about their finances to the FTC when they agreed to settle deceptive advertising charges in 2014. U.S. District Court Judge Neil V. Wake lifted the suspension of the monetary judgment entered […]
FTC Brings Action Against Debt Relief Operation that Targeted Financially Distressed Homeowners and Student Loan Borrowers
The Federal Trade Commission has charged a debt relief operation with falsely representing to financially distressed homeowners and student loan borrowers that it would help get their mortgages and student loans modified. At the FTC’s request, a federal court has temporarily halted the operation. The agency seeks to permanently stop the alleged illegal practices and […]
FTC Approves Final Order Prohibiting “Ultimeyes” Manufacturer from Making Deceptive Claims that the App Can Improve Users’ Vision
Following a public comment period, the Federal Trade Commission has approved a final consent order with Carrot Neurotechnology, Inc. and its co-owners, requiring them to stop making deceptive claims that their “Ultimeyes” app can improve users’ vision. According to the FTC’s complaint, ads for Ultimeyes falsely stated that the app would “Turn Back The Clock […]
ASUS Settles FTC Charges That Insecure Home Routers and “Cloud” Services Put Consumers’ Privacy At Risk
Taiwan-based computer hardware maker ASUSTeK Computer, Inc. has agreed to settle Federal Trade Commission charges that critical security flaws in its routers put the home networks of hundreds of thousands of consumers at risk. The administrative complaint also charges that the routers’ insecure “cloud” services led to the compromise of thousands of consumers’ connected storage […]
FTC Approves Modified Consent Order for Mylan N.V.
The Federal Trade Commission has approved a modified final order settling charges that Mylan N.V.’s proposed hostile takeover of Perrigo Company plc would harm competition. Because Mylan failed to obtain the required threshold of Perrigo shares to succeed in its unsolicited offer, Mylan has abandoned the proposed acquisition. Accordingly, the Commission has issued a modified […]
FTC Files Action Against Stratford Career Institute for Misleading Consumers About Online High School ‘Diploma’ Course
The Federal Trade Commission has charged online distance education school Stratford Career Institute with misleading consumers about its high school equivalency program that the agency alleges failed to meet the basic requirements set by most states. In its complaint, the FTC alleges that Stratford’s extensive advertising for its high school program included multiple references to […]
FTC Puts Conditions on Generic Drug Marketer Lupin Ltd.’s Proposed Acquisition of Gavis Pharmaceuticals LLC
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC will sell the rights and assets for two generic drugs, one used to treat bacterial infections and the other to treat ulcerative colitis, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive. The proposed consent order preserves […]
FTC Requires Drug Marketer Hikma Pharmaceuticals PLC to Divest Rights to Five Generic Injectable Drugs as a Condition of Acquiring Certain Drug Products from Ben Venue Laboratories, Inc.
The Federal Trade Commission will require generic drug marketer Hikma Pharmaceuticals PLC to divest its rights and interests in five generic injectable pharmaceuticals, as part of a settlement resolving charges that Hikma’s $5 million acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. would likely be anticompetitive. Under […]